SCMOM 2012_The Clinical Outlook for Regenerative Medicine – Video

Posted: November 28, 2012 at 12:43 pm




SCMOM 2012_The Clinical Outlook for Regenerative Medicine
As many regenerative medicine and cell therapy products move into clinical trials, a clearer understanding of how these products will perform clinically is critical for achieving regulatory approval and ultimately, for commercialization. This session will discuss the major clinical events expected to drive the regenerative medicine sector over the next two years, as well as address some of the key issues facing these products as they approach the marketplace. Moderator: Greg Lucier, MBA, Chairman and CEO, Life Technologies Panelists: Jay Siegel, MD, Chief Biotechnology Officer and Head, Global Pharmaceutical Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson Johnson Paul Simmons, Ph.D., Executive Vice President, Corporate Research and Product Development, Mesoblast Limited Matthias Steger, Ph.D., MBA, Global Head Research and Technology Partnering, Roche Ltd. Dean Tozer, Vice President, Corporate Development, Shire Regenerative MedicineFrom:AllianceRegenMedViews:5 1ratingsTime:01:16:22More inScience Technology

See the article here:
SCMOM 2012_The Clinical Outlook for Regenerative Medicine - Video

Related Posts

Comments are closed.

Archives